The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health: a major step towards structuring the European microbiome excellence sector
May 14 2024 - 5:53AM
The Alliance Promotion Microbiote is
becoming the European Microbiome Innovation for Health: a major
step towards structuring the European microbiome excellence
sector
Paris - France - May 14, 2024 - The
Alliance Promotion Microbiome (APM), a key player dedicated to the
development, production, and commercialization of therapeutic
innovations based on the microbiome, announces today its
expansion across Europe and its rebranding as the European
Microbiome Innovation for Health (EMIH) association. This
transition marks a pivotal moment in solidifying and advancing
Europe's industrial microbiome sector, with the goal of fostering
medical innovation and securing a prominent global position for
European stakeholders to enhance patients' health by addressing
unmet medical needs.
Beyond a simple change of name, the aim is to
formalize the decision to operate at the European level,
recognizing its paramount significance due to its critical capacity
to drive positive outcomes in research and development,
consequently enhancing public health. This choice is underscored by
the escalating global competition and underscores the imperative to
address the burgeoning realities within the maturing European
landscape. This comes at a pivotal moment when the European Union
is structuring and displaying major ambitions in terms of health
with structuring texts such as SoHO - to be implemented - and the
pharmaceutical package - to be brought to a successful conclusion -
not forgetting strategic programs such as EU4Health. Each
initiative carries profound implications, shaping the trajectory of
leveraging the vast potential of microbiome for the health of
patients and the European economy.
EMIH is an independent European coalition, a
public and private initiative and a non-profit organization aiming
to ensure that microbiome-based medical innovations become a public
health priority in the European Union.
Its members are committed to advancing knowledge
and the emergence of therapeutic bioproductions, diagnostics, and
medical devices based on the microbiome in the field of human
health, ensuring equal access through regulatory frameworks meeting
the highest quality standards, while also maintaining economic
balance to sustain therapeutic innovation.
The EMIH believes that only major action at this
level will make it possible to structure a leading microbiome
sector in Europe, providing the European ecosystem with a key
global position to accelerate the emergence of innovative
microbiome-based therapies. Such advancements represent a profound
and significant paradigm shift in the approach to healthcare for
all.
"European microbiome actors distinguish themselves with
innovative R&D and their significant roles within the global
sector. They are recognized for their pursuit of excellence and
hold leadership positions in their respective fields. By uniting
our efforts within EMIH, our goal is to bring microbiome medical
innovation to one of the most promising sectors and to prioritize
it within the European Union's public health agenda. Our ambition
is to make these advancements accessible to all patients. Thus, we
invite all European entities engaged in microbiome research to
submit their applications to join EMIH. Together, let's make
microbiome the flagship of European health innovation,"
states Hervé Affagard, President-elect of
EMIH.
About European Microbiome Innovation for
Health (formerly known as Alliance Promotion
Microbiome-APM) EMIH is an independent coalition within
the European Union, the United Kingdom, and Switzerland, currently
comprising 20 major players from the public and private sectors.
From the laboratory to the patient's bedside, EMIH covers the
entire value chain of the microbiome industry. Its goal is to
position Europe as a global leader in the development, production,
and commercialization of microbiome-based therapeutic innovations.
EMIH members include Bioaster, Biocodex, Biofortis, Biose
Industrie, Cynbiome, Eligo Bioscience, Ferring Pharmaceuticals, GMT
Science, INRAE, Lallemand Health Solutions, Lyonbiopôle, Pelican
Health, MaaT Pharma, Microbiome Foundation, Polepharma, Medicen
Paris Région, Nexbiome, Novobiome, Seventure Partners, and
Skyepharma.
Contacts for European Microbiome Innovation for
Health Media - E-mail:
pri@frenchmicrobiome.orgMemberships & Applications
- E-mail: contact@frenchmicrobiome.org